Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan Conditioning for Allo-HSCT in Lymphatic Malignancies
NCT01079013Phase 2Unknown
- Sponsor
- Sheba Medical Center
- Start
- Mar 2010
- Primary completion
- Apr 2018
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of treosulfan in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by Sheba Medical Center. Primary endpoint: Disease-Free Survival at 2 years. Status: unknown.
02
Drugs
treosulfan
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01079013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01079013.